Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).

Villaruz LC, Jin J, Wang H, Lee JJ, Luke JJ, Rhee JC, Waqar SN, Shapiro GI, Cleary J, Davar D, Burns TF, Verma R, Amin M, Appleman L, Ciombor KK, Davis EJ, Riess JW, Dees EC, Kim EJ, Cardin D, Guo J, Christner SM, Deppas J, Parise AM, Schmitz JC, Guerrouahen BS, Suchko M, Contreras A, Li L, Ferry-Galow KV, Chang TC, Jiwani S, Bakkenist CJ, Chu E, Gore SD, Beumer JH.

Open source

DOI: 10.1002/cncr.70157
Published: 2025-11-01
Container: Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cncr.70157,
  title = {Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).},
  author = {Villaruz LC and  Jin J and  Wang H and  Lee JJ and  Luke JJ and  Rhee JC and  Waqar SN and  Shapiro GI and  Cleary J and  Davar D and  Burns TF and  Verma R and  Amin M and  Appleman L and  Ciombor KK and  Davis EJ and  Riess JW and  Dees EC and  Kim EJ and  Cardin D and  Guo J and  Christner SM and  Deppas J and  Parise AM and  Schmitz JC and  Guerrouahen BS and  Suchko M and  Contreras A and  Li L and  Ferry-Galow KV and  Chang TC and  Jiwani S and  Bakkenist CJ and  Chu E and  Gore SD and  Beumer JH.},
  year = {2025},
  journal = {Cancer},
  doi = {10.1002/cncr.70157},
  url = {https://doi.org/10.1002/cncr.70157}
}

RIS

TY  - JOUR
TI  - Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).
AU  - Villaruz LC
AU  -  Jin J
AU  -  Wang H
AU  -  Lee JJ
AU  -  Luke JJ
AU  -  Rhee JC
AU  -  Waqar SN
AU  -  Shapiro GI
AU  -  Cleary J
AU  -  Davar D
AU  -  Burns TF
AU  -  Verma R
AU  -  Amin M
AU  -  Appleman L
AU  -  Ciombor KK
AU  -  Davis EJ
AU  -  Riess JW
AU  -  Dees EC
AU  -  Kim EJ
AU  -  Cardin D
AU  -  Guo J
AU  -  Christner SM
AU  -  Deppas J
AU  -  Parise AM
AU  -  Schmitz JC
AU  -  Guerrouahen BS
AU  -  Suchko M
AU  -  Contreras A
AU  -  Li L
AU  -  Ferry-Galow KV
AU  -  Chang TC
AU  -  Jiwani S
AU  -  Bakkenist CJ
AU  -  Chu E
AU  -  Gore SD
AU  -  Beumer JH.
PY  - 2025
JO  - Cancer
DO  - 10.1002/cncr.70157
UR  - https://doi.org/10.1002/cncr.70157
ER  -

APA

LC, V., J, J., H, W., JJ, L., JJ, L., JC, R., SN, W., GI, S., J, C., D, D., TF, B., R, V., M, A., L, A., KK, C., EJ, D., JW, R., EC, D., EJ, K., D, C., J, G., SM, C., J, D., AM, P., JC, S., BS, G., M, S., A, C., L, L., KV, F., TC, C., S, J., CJ, B., E, C., SD, G., & JH., B. (2025). Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).. Cancer. https://doi.org/10.1002/cncr.70157

Source records

europe-pmc · retrieved 2026-09-26T10:49:57.666Z